| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3564 | Nav1.7 Blocker-801 | Potent NaV1.7 blocker, being 5-10 fold more potent than NaV 1.2 and NaV 1.6 |
|
| DCC3565 | Navarixin | Novel CXC chemokine receptor 2 (CXCR2) antagonist |
|
| DCC3566 | Naveglitazar | Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist |
|
| DCC3567 | Naxifylline | Potent and selective A1 adenosine receptor antagonist |
|
| DCC3568 | Nb-360 | Biological Active Reagents |
|
| DCC3569 | Nb-caged Tyrosine Hydrochloride | L-Tyrosine caged with photosensitive ortho-nitrobenzyl side chain |
|
| DCC3570 | Nbd-09027 | Novel HIV-1 entry inhibitor |
|
| DCC3571 | Nbd-10007 | Novel HIV-1 entry inhibitor |
|
| DCC3572 | Nbd-14136 | Novel CD4-mimetic HIV-1 entry inhibitor |
|
| DCC3573 | N-bn-thaz Fumarate | Potent agonist of the human 5-HT2A and 5-HT2C receptors |
|
| DCC3574 | Nboh-2c-cn Hydrochloride | Potent and selective 5-HT2A receptor agonist |
|
| DCC3575 | Nbti-5463 | Novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy |
|
| DCC3576 | nc00094221 | M. tuberculosis Dihydrofolate Reductase Inhibitor |
|
| DCC3577 | Nc2213 | Novel inhibitor of methionine aminopeptidase 2 (MetAP2) |
|
| DCC3578 | Ncats-sm1440 | First-in-class, potent, and selective Lactate dehydrogenase inhibitor |
|
| DCC3579 | Ncats-sm1441 | First-in-class, potent, and selective Lactate dehydrogenase inhibitor |
|
| DCC3580 | Ncb0970 | Less active trans-isomer of NCB-0846, acting as the negative control for NCB-0846, showing 13-fold weaker TNIK enzyme-inhibitory activity |
|
| DCC3581 | Ncdm-32 | Potent pan KDM Inhibitor, inhibiting KDM2A, KDM7A, KDM7B, KDM4A, KDM4C, and KDM5A |
|
| DCC3582 | Ncgc00117362 | Novel inhibitor of ovarian cancer metastasis, adhesion, invasion and proliferation |
|
| DCC3583 | Ncgc00120943 | Novel Agonist for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions |
|
| DCC3584 | ncgc00161856 | The first small-molecule inverse agonist for the thyroid-stimulating hormone receptor (TSHR) |
|
| DCC3585 | ncgc00242595 | TSHR neutral antagonist, inhibiting stimulated signaling but not basal signaling |
|
| DCC3586 | Ncgc00249987 | Novel allosteric Eya2 phosphatase inhibitor, specifically targeting migration, invadopodia formation, and invasion of lung cancer cells |
|
| DCC3587 | Ncgc00262654 | Novel AMA1-RON2 Inhibitor |
|
| DCC3588 | Ncgc2327 | Novel potent inhibitor of IRAK1/4 and FLT3 |
|
| DCC3589 | Nco-04 | Novel SIRT1 inhibitor, inducing cell death in adult T-cell leukaemia cells |
|
| DCC3590 | Ncrw0005-f05 | Novel GPR139 receptor agonist |
|
| DCC3591 | Ncs-382 | Analogue of γ-hydroxybutyric acid (GHB), acting as a substrate for both the monocarboxylate transporter subtype 1 (MCT1) and subtype 4 (MCT4) |
|
| DCC3592 | Ncs-8591 | Beclin 1 mimetic, selectively binding to Bcl-xL and inducing autophagy, showing potent cytotoxicity in PC-3, PC-3a and DU145 prostate cancer cells |
|
| DCC3593 | Nctu-alan-2026 | Novel blocker of the interaction between FGF1 and FGFRD2 to inhibit cell proliferation, showing potent antiproliferent with less cytotoxicity. |
|
